Découvrez nos professeurs et professeures!

Revenir au répertoire
Fiche précédente
Fiche suivante

Paul Toren

Médecin clinicien enseignant agrégé

Paul Toren
paul.toren.1@ulaval.ca
Centre de recherche sur le cancer
Centre de recherche du CHU de Québec - Université Laval
Partager la fiche :

Contribution à la recherche

Thématiques de recherche de la Faculté de médecine

  • Oncologie

Domaines de recherche

  • Métastases et progression du cancer
  • Oncologie clinique
  • Immunologie des tumeurs

Projets de recherche en cours

  • Étude des interactions endo-immunitaires pour améliorer le traitement des carcinomes urothéliaux - Fonds de recherche du Québec - Santé - Chercheurs-boursiers cliniciens - Juniors 1 et 2, Seniors, chercheur principal - 2024-07-01 au 2028-06-30
  • Gut microbiota biomarkers to personalize treatment of bladder cancer - The W. Garfield Weston Foundation - Proof-of-Principle 2024: Microbial biomarkers of disease and therapeutic response, co-chercheur - 2024-12-01 au 2027-04-30
  • Targeting sex steroids to improve the response to bladder cancer immunotherapy - Instituts de recherche en santé du Canada - Subvention Projet, chercheur principal - 2021-10-01 au 2026-09-30
  • Circulating basophils and eosinophils as novel biomarkers for non-muscle invasive cancer bladder cancer - Société de recherche sur le cancer - Subvention de fonctionnement, chercheur principal - 2024-09-01 au 2026-08-31
  • Repurposing bicalutamide to improve the response to immune checkpoint inhibition for treatment of advanced urothelial carcinoma - Société de recherche sur le cancer - UpCycle 2.1, co-chercheur - 2022-08-01 au 2026-07-31

Financements des 2 dernières années

  • Exploiter les interactions endocriniennes-immunes pour améliorer le traitement des cancers urologiques - Fonds de recherche du Québec - Santé - Chercheurs-boursiers cliniciens - Juniors 1 et 2, Seniors, chercheur principal - 2022-07-01 au 2024-06-30

Publications

  • 236 EXPERIENCE WITH RECTOURETHRAL FISTULA REPAIR AND DESCRIPTION OF A NOVEL SURGICAL TECHNIQUE, Sender Herschorn, Paul Toren, Ashley Cox, The Journal of Urology, 2012, 10.1016/j.juro.2012.02.291
  • Sex steroids in the tumor microenvironment and prostate cancer progression, Paul Toren, Clovis Boibessot, Endocrine-Related Cancer, 2018, 10.1530/erc-17-0493
  • Combined AKT and MEK Pathway Blockade in Pre-Clinical Models of Enzalutamide-Resistant Prostate Cancer, Amina Zoubeidi, Fraser Johnson, Soojin Kim, Paul Toren, PLOS ONE, 2016, 10.1371/journal.pone.0152861
  • Images - Para-aortic lymphatic ectasia suggestive of testicular cancer retroperitoneal metastasis., Toren P, Chahine S, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021, 10.5489/cuaj.6677
  • Effects of Concentrated Long-Chain Omega-3 Polyunsaturated Fatty Acid Supplementation on Quality of Life after Radical Prostatectomy: A Phase II Randomized Placebo-Controlled Trial (RCT-EPA)., Fradet V, Julien P, Duchesne T, Caumartin Y, Dujardin T, Tiguert R, Toren P, Lodde M, Lacombe L, Fradet Y, Tourigny R, Pelletier JF, Robitaille K, Moussa H, Nutrients, 2023, 10.3390/nu15061369
  • Northeastern Section of the AUA 72nd Annual Meeting Abstracts, , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2020
  • CYCLOPHOSPHAMIDE INDUCED HEMORRHAGIC CYSTITIS SUCCESSFULLY TREATED WITH PENTOSANPOLYSULPHATE, RICHARD W. NORMAN, PAUL J. TOREN, The Journal of Urology, 2005, 10.1097/01.ju.0000146626.78180.83
  • CUA 2022 Annual Meeting Abstracts - Poster Session 7: Oncology - Bladder Sunday, June 26, 2022 • 07:30-09:00., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2022, 10.5489/cuaj.7929
  • 2015 CUA Abstracts., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2015
  • Neutrophil-to-lymphocyte Ratio as a Predictive Marker of Response to Abiraterone Acetate: A Retrospective Analysis of the COU302 Study., Toren P, Fradet V, Pouliot F, Nguile-Makao M, Loubersac T, European urology oncology, 2019, 10.1016/j.euo.2019.01.009
  • Exercise effects on adipokines and the IGF axis in men with prostate cancer treated with androgen deprivation: A randomized study., Ritvo P, Trachtenberg J, Matthew AG, Guglietti C, Toren P, Alibhai SM, Connor MK, Santa Mina D, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2013, 10.5489/cuaj.235
  • Comparison of epidural and intravenous patient controlled analgesia in patients undergoing radical cystectomy., Fleshner N, McCluskey S, Ma C, Ladak S, Toren P, The Canadian journal of urology, 2009
  • CUA 2022 Annual Meeting Abstracts - Poster Session 9: Oncology - Prostate Sunday, June 26, 2022 • 07:30-09:00., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2022, 10.5489/cuaj.7931
  • PD32-01 PRE-CLINICAL RATIONALE FOR COMBINATION PI3K AND BRD4 INHIBITION IN ADVANCED PROSTATE CANCER, Amina Zoubeidi, Soojin Kim, Jared Allman, Paul Toren, The Journal of Urology, 2016, 10.1016/j.juro.2016.02.677
  • Expression of programmed death ligand-1 (PD-L1) in metastatic and postchemotherapy viable testicular germ cell tumors., Toren P, Périgny M, Rendon R, Power N, Frees S, Joubert P, Haferkamp A, Wagner DC, Duguay J, Al-Hogbani M, Urologic oncology, 2021, 10.1016/j.urolonc.2021.02.014
  • Contemporary outcomes of palliative transurethral resection of the prostate in patients with locally advanced prostate cancer, Paul Toren, Louis Lacombe, Yves Fradet, Anne-Sophie Julien, Sarah-Jeanne Cyr, Joanie Pelletier, Urologic Oncology: Seminars and Original Investigations, 2018, 10.1016/j.urolonc.2018.05.004
  • Anticancer activity of a novel selective CYP17A1 inhibitor in preclinical models of castrate-resistant prostate cancer., Gleave ME, Moore W, Zoubeidi A, Guns ES, Adomat H, Mangalji A, Pham S, Kim S, Toren PJ, Molecular cancer therapeutics, 2015, 10.1158/1535-7163.mct-14-0521
  • Prostate cancer resistance leads to a global deregulation of translation factors and unconventional translation of long non-coding RNAs, Hussein SMI, Mazroui R, Toren P, Lambert J, Zoubedi A, Grenier VS, Khelifi G, Joncas F, Adjibade P, Lelong EIJ, 2021, 10.1101/2021.01.05.425492
  • The patient presenting with genitourinary AIDS, Wendy Wobeser, Paul Toren, Supportive Care for the Urology Patient, 2005, 10.1093/acprof:oso/9780198529415.003.0017
  • Pre-clinical rationale for combination PI3K and BRD4 inhibition in advanced prostate cancer., Jared Allman, Amina Zoubeidi, Paul Toren, Journal of Clinical Oncology, 2016, 10.1200/jco.2016.34.2_suppl.234
  • Use of a novel parenchymal clamp for laparoscopic and open partial nephrectomy, Umesh Jain, Anthony Mclean, Turki Al-Essawi, Paul Toren, Canadian Urological Association Journal, 2013, 10.5489/cuaj.936
  • Active surveillance in patients with a PSA >10 ng/mL, Antonio Finelli, Neil Fleshner, John Trachtenberg, Shabbir Alibhai, Narhari Timilshina, Lih-Ming Wong, Paul Toren, Canadian Urological Association Journal, 2014, 10.5489/cuaj.2121
  • Switching Cancers: A Systematic Review Assessing the Role of Androgen Suppressive Therapy in Bladder Cancer, Paul Toren, Richard T. Bryan, Alexandre Zlotta, Michele Lodde, Catherine McMartin, Kassim Kourbanhoussen, European Urology Focus, 2021, 10.1016/j.euf.2020.10.002
  • Novel non-AR therapeutic targets in castrate resistant prostate cancer., Gleave ME, Toren PJ, Translational andrology and urology, 2013, 10.3978/j.issn.2223-4683.2013.09.09
  • Supplementary Figures 1-3, Supplementary Tables 1-5 from Serum Sex Steroids as Prognostic Biomarkers in Patients Receiving Androgen Deprivation Therapy for Recurrent Prostate Cancer: A Post Hoc Analysis of the PR.7 Trial, Laurence Klotz, Chantal Guillemette, Éric Lévesque, Yves Fradet, Frédéric Pouliot, Patrick Caron, Véronique Turcotte, France-Hélène Joncas, Keyue Ding, Azik Hoffman, Paul Toren, 2023, 10.1158/1078-0432.22475735
  • Reply, Antonio Finelli, Paul Toren, Urology, 2013, 10.1016/j.urology.2013.04.056
  • Opioid use after uro-oncologic surgeries in time of opioid crisis., Lodde M, Caumartin Y, Toren P, Tremblay S, Jacques E, Turcotte B, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2022, 10.5489/cuaj.7633
  • Résumés AUQ 2021., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021, 10.5489/cuaj.7674
  • Discordance between testosterone measurement methods in castrated prostate cancer patients., Pouliot F, Guérette D, Saad F, Klotz L, Lacombe L, Guillemette C, Toren P, Fradet Y, Dubois G, Thériault B, Déry M, Lemire F, Rouleau M, Endocrine connections, 2019, 10.1530/ec-18-0476
  • The Neutrophil-to-Lymphocyte Ratio as a Biomarker in Metastatic Castrate-Sensitive Prostate Cancer Patients Treated with Abiraterone Acetate, Paul Toren, Marie-Laurence Roy, Caio Vinícius Suartz, Société Internationale d’Urologie Journal, 2024, 10.3390/siuj5040044
  • Diet, Obesity, and Cancer Progression: Are Adipocytes the Link?, Vasundara Venkateswaran, Benjamin C. Mora, Paul Toren, Lipid Insights, 2013, 10.4137/lpi.s10871
  • Combining Antiandrogens with Immunotherapy for Bladder Cancer Treatment., Toren P, Fradet Y, Bergeron A, Picard V, Joncas FH, Gris T, Besançon M, European urology open science, 2022, 10.1016/j.euros.2022.06.007
  • Effect of dutasteride on clinical progression of benign prostatic hyperplasia in asymptomatic men with enlarged prostate: a post hoc analysis of the REDUCE study., Fleshner N, Zlotta A, Finelli A, Kulkarni G, Margel D, Toren P, BMJ (Clinical research ed.), 2013, 10.1136/bmj.f2109
  • Extensive Alteration of Androgen Precursor Levels After Castration in Prostate Cancer Patients and Their Association With Active Androgen Level., Pouliot F, Guillemette C, Lévesque É, Turcotte V, Lacombe L, Toren P, Morin F, Caron P, Neveu B, Rouleau M, The Journal of urology, 2022, 10.1097/ju.0000000000002923
  • MP62-06 COMBINED AKT AND MEK PATHWAY BLOCKADE IN PRE-CLINICAL MODELS OF ENZALUTAMIDE-RESISTANT PROSTATE CANCER, Amina Zoubeidi, Soojin Kim, Paul Toren, The Journal of Urology, 2016, 10.1016/j.juro.2016.02.914
  • Supplementary Figures 1-3, Supplementary Tables 1-5 from Serum Sex Steroids as Prognostic Biomarkers in Patients Receiving Androgen Deprivation Therapy for Recurrent Prostate Cancer: A Post Hoc Analysis of the PR.7 Trial, Laurence Klotz, Chantal Guillemette, Éric Lévesque, Yves Fradet, Frédéric Pouliot, Patrick Caron, Véronique Turcotte, France-Hélène Joncas, Keyue Ding, Azik Hoffman, Paul Toren, 2023, 10.1158/1078-0432.22475735.v1
  • A prospective, multisite study analyzing the percentage of urological cases that can be completely managed by telemedicine., Pouliot F, Lacombe L, Fradet Y, Dujardin T, Deschênes-Rompré MP, Cloutier J, Caumartin Y, Bureau M, Bolduc S, Blouin AC, Blais AS, Paquet S, Turcotte B, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2020, 10.5489/cuaj.6862
  • Images - Sclerosing mesenteritis presenting with unilateral hydro-ureteronephrosis., Cloutier J, Toren P, Turcotte B, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2019, 10.5489/cuaj.5689
  • Analysis of sex-based differences to Bacillus Calmette-Guérin for non-muscle invasive bladder cancer., Toren P, Fradet Y, Lacombe L, Lodde M, Fradet V, Simonyan D, Fadel J, Urologic oncology, 2022, 10.1016/j.urolonc.2022.09.024
  • Effects of omega‐3 supplementation on psychological symptoms in men with prostate cancer: Secondary analysis of a double‐blind placebo‐controlled randomized trial, Vincent Fradet, Karine Robitaille, Yves Fradet, Michele Lodde, Frédéric Pouliot, Paul Toren, Thierry Dujardin, Yves Caumartin, Rabi Tiguert, Louis Lacombe, Pierre Julien, Jean‐François Pelletier, Hanane Moussa, Josée Savard, Cancer Medicine, 2023, 10.1002/cam4.6598
  • Salvage therapy for BCG failure with intravesical sequential gemcitabine and docetaxel in patients with recurrent NMIBC., Lodde M, Toren P, Pouliot F, Fradet V, Fradet Y, Lacombe L, Marcotte N, Garneau CA, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2024, 10.5489/cuaj.8341
  • Reply by Authors, Paul Toren, Laurence Klotz, Keyue Ding, Juanita M. Crook, Frédéric Pouliot, Lily Summers-Trasiewicz, Samuel Tremblay, Journal of Urology, 2021, 10.1097/JU.0000000000001946.03
  • Use and duration of antibiotic prophylaxis and the rate of urinary tract infection after radical cystectomy for bladder cancer: Results of a multicentric series., Lodde M, Toren P, Fradet Y, Lacombe L, Lemire F, Pycha A, Comploj E, Fradet V, Fritsche HM, Tandogdu Z, Mayr R, Ladurner C, Haider M, Urologic oncology, 2019, 10.1016/j.urolonc.2019.01.017
  • Androgen receptor and immune cell PD-L1 expression in bladder tumors predicts disease recurrence and survival, Yves Fradet, Alain Bergeron, Louis Lacombe, Hélène Hovington, David Simonyan, Hervé Brisson, Paul Toren, World Journal of Urology, 2021, 10.1007/s00345-020-03358-x
  • Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT., Crook JM, Gospodarowicz M, Goldenberg L, Malone S, Horwitz E, Higano CS, Dearnaley D, Toren P, Ding K, O'Callaghan C, Klotz L, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, 10.1200/jco.2014.58.2973
  • Podium Session 1: Prostate Cancer June 26, 2016 1050–1150., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2016
  • Effects of omega-3 fatty acids supplementation on perioperative blood loss and complications after radical prostatectomy, Vincent Fradet, Karine Robitaille, Yves Fradet, Rabi Tiguert, Thierry Dujardin, Michele Lodde, Paul Toren, Louis Lacombe, Narcisse Singbo, Jean-François Pelletier, Samuel Fradet, Clinical Nutrition ESPEN, 2022, 10.1016/j.clnesp.2021.12.011
  • High infiltration of CD209+ dendritic cells and CD163+ macrophages in the peritumor area of prostate cancer is predictive of late adverse outcomes., Fradet Y, Bergeron A, Toren P, Lacombe L, Fradet V, Têtu B, Hovington H, Simonyan D, LaRue H, Molina OE, Frontiers in immunology, 2023, 10.3389/fimmu.2023.1205266
  • Prognostic value of urinary prostate cancer antigen 3 (PCA3) during active surveillance of patients with low‐risk prostate cancer receiving 5α‐reductase inhibitors, Yves Fradet, Thierry Dujardin, Rabi Tiguert, Frédéric Pouliot, Louis Lacombe, Tal Ben‐Zvi, Alain Bergeron, André Caron, Caroline Léger, Jérome Lévesque, Michele Lodde, Molière Nguile‐Makao, Paul Toren, Vincent Fradet, BJU International, 2018, 10.1111/bju.14041
  • Lyn tyrosine kinase regulates androgen receptor expression and activity in castrate-resistant prostate cancer., Zoubeidi A, Bishop JL, Cox ME, Gust KM, Lamoureux F, Fazli L, Beraldi E, Vahid S, Toren P, Thaper D, Nip KM, Zardan A, Oncogenesis, 2014, 10.1038/oncsis.2014.30
  • Circulating Basophils as a Prognostic Marker for Response to Bacillus Calmette-Guérin, Paul Toren, Peter C. Black, Jonathan Fadel, Typhaine Gris, Raphaëlla Rosebush-Mercier, Timo Nykopp, Geneviève Trépanier, Clinical Genitourinary Cancer, 2024, 10.1016/j.clgc.2023.12.004
  • Résumés AUQ 2019., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2019, 10.5489/cuaj.6229
  • Periprostatic Adipose Tissue and Prostate Cancer Progression: New Insights into the Tumor Microenvironment, Vasundara Venkateswaran, Paul Toren, Clinical Genitourinary Cancer, 2014, 10.1016/j.clgc.2013.07.013
  • Serum Sex Steroids as Prognostic Biomarkers in Patients Receiving Androgen Deprivation Therapy for Recurrent Prostate Cancer: A Post Hoc Analysis of the PR.7 Trial, Laurence Klotz, Chantal Guillemette, Éric Lévesque, Yves Fradet, Frédéric Pouliot, Patrick Caron, Véronique Turcotte, France-Hélène Joncas, Keyue Ding, Azik Hoffman, Paul Toren, Clinical Cancer Research, 2018, 10.1158/1078-0432.CCR-18-1187
  • Point-of-care clinical documentation: assessment of a bladder cancer informatics tool (eCancerCareBladder): a randomized controlled study of efficacy, efficiency and user friendliness compared with standard electronic medical records., Jewett MA, Grober ED, Fleshner NE, Finelli A, Zlotta AR, Chagpar A, Legere L, Lane K, Liu J, Truong T, Chow R, Xi H, Toren PJ, Bostrom PJ, Journal of the American Medical Informatics Association : JAMIA, 2011, 10.1136/amiajnl-2011-000221
  • Building a Canadian Translational Bladder Cancer Research Network., Canadian Bladder Cancer Research Network, Black PC, Kassouf W, Mansure J, Fradet Y, Fradet V, Purves R, Hardy C, Eigl BJ, Toren P, Wang E, Lange D, Siemens DR, Berman DM, Koti M, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2020, 10.5489/cuaj.6887
  • Extragonadal Steroids Contribute Significantly to Androgen Receptor Activity and Development of Castration Resistance in Recurrent Prostate Cancer after Primary Therapy., Guillemette C, Klotz L, Lévesque É, Lacombe L, Caron P, Ding K, Vélot L, Morin F, Toren P, Neveu B, Rouleau M, Pouliot F, The Journal of urology, 2020, 10.1097/ju.0000000000000699
  • The sex gap in bladder cancer survival — a missing link in bladder cancer care?, Richard T. Bryan, Ananya Choudhury, Taha Lodhi, Roger Kockelbergh, Typhaine Gris, Amy Burley, Keval Patel, Anna Wilkins, Paul Toren, Nature Reviews Urology, 2024, 10.1038/s41585-023-00806-2
  • Androgen deprivation therapy in advanced prostate cancer: is intermittent therapy the new standard of care?, Toren P, Klotz L, Current oncology (Toronto, Ont.), 2012, 10.3747/co.19.1298
  • Re: Shilo Y, Zisman A, Lindner A, et al. The predominance of benign histology in small testicular masses. Urol Oncol 2012;30:719-22., Lo K, Toren P, Urologic oncology, 2013, 10.1016/j.urolonc.2012.11.018
  • Perception and satisfaction of patients after telemedicine urology consultations: A matched analysis with physicians' perspective., Pouliot F, Dujardin T, Deschênes-Rompré MP, Cloutier J, Caumartin Y, Bureau M, Bolduc-Mokhtar A, Bolduc S, Blouin AC, Blais AS, Bélanger L, Turcotte B, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2022, 10.5489/cuaj.7819
  • Receipt of 5-Alpha Reductase Inhibitors Before Radical Cystectomy: Do They Render High-Grade Bladder Tumors Less Aggressive?, Paul Toren, Michele Lodde, Yves Fradet, Vincent Fradet, Louis Lacombe, Catherine McMartin, Clinical Genitourinary Cancer, 2019, 10.1016/j.clgc.2019.07.016
  • Plasma extracellular vesicles as phenotypic biomarkers in prostate cancer patients, Paul Toren, Caroline Gilbert, Yves Fradet, Frédéric Pouliot, Hon Sing Leong, Fannie Morin, Mélanie Rouleau, Fabrice Lucien, France‐Hélène Joncas, The Prostate, 2019, 10.1002/pros.23901
  • Case - Gigantic obstructive calculi in continent urinary diversion., Toren P, Lodde M, Akoum N, Fadel J, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2022, 10.5489/cuaj.7698
  • CUA 2023 Annual Meeting Abstracts - Poster Session 9: Oncology - Prostate (Part 2) Sunday, June 25, 2023 • 7:00-8:30., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2023, 10.5489/cuaj.8417
  • Catastrophic sepsis and hemorrhage following transrectal ultrasound guided prostate biopsies., Trachtenberg J, Razik R, Toren P, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2010
  • Results of a national population-based study of outcomes of surgery for renal tumors associated with inferior vena cava thrombus., Finelli A, Alibhai S, Kulkarni G, Timilshina N, Abouassaly R, Toren P, Urology, 2013, 10.1016/j.urology.2013.04.054
  • Use of a novel parenchymal clamp for laparoscopic and open partial nephrectomy., Jain U, McLean A, Al-Essawi T, Toren P, Canadian Urological Association Journal, 2010
  • Data from Serum Sex Steroids as Prognostic Biomarkers in Patients Receiving Androgen Deprivation Therapy for Recurrent Prostate Cancer: A Post Hoc Analysis of the PR.7 Trial, Laurence Klotz, Chantal Guillemette, Éric Lévesque, Yves Fradet, Frédéric Pouliot, Patrick Caron, Véronique Turcotte, France-Hélène Joncas, Keyue Ding, Azik Hoffman, Paul Toren, 2023, 10.1158/1078-0432.c.6529157.v1
  • Follicle-stimulating hormone (FSH) levels prior to prostatectomy are not related to long-term oncologic or cardiovascular outcomes for men with prostate cancer., Toren P, Lacombe L, Guillemette C, Fradet Y, Dagenais F, Hovington H, D Wallis CJ, Kourbanhoussen K, Joncas FH, Asian journal of andrology, 2022, 10.4103/aja.aja_58_21
  • EDITORIAL COMMENT., Toren P, Urology, 2020, 10.1016/j.urology.2019.11.057
  • Abstraits AUQ 2018, Zorn K, Toren P, Dubois G, Thériault B, Déry M, Rouleau M, Lemire F, Kassouf W, Mansure J, Seuntjens J, Piccirilo C, Shinde S, Ayoub M, Rompré-Brodeur A, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2018
  • NS-AUA 2023 Annual Meeting Abstracts - Oncology - Bladder, Renal, Testes., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2023, 10.5489/cuaj.8577
  • 2017 NSAUA Abstracts., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2017, 10.5489/cuaj.4896
  • 2018 CUA Abstracts., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2018
  • 2009 CUA Abstracts., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2009
  • Subversion of infiltrating prostate macrophages to a mixed immunosuppressive tumor-associated macrophage phenotype., Toren P, Fradet Y, Bergeron A, Bilodeau S, Fradet V, Pouliot F, Pelletier JF, Neveu B, Champagne A, Tav C, Lachance G, Molina O, Boibessot C, Clinical and translational medicine, 2022, 10.1002/ctm2.581
  • Prostate cancer resistance leads to a global deregulation of translation factors and unconventional translation., Hussein SMI, Mazroui R, Toren P, Lambert JP, Audet-Walsh E, Zoubeidi A, Gris T, Paquette V, Grenier St-Sauveur V, Joncas FH, Adjibade P, Khelifi G, Lelong EIJ, NAR cancer, 2022, 10.1093/narcan/zcac034
  • Data from Serum Sex Steroids as Prognostic Biomarkers in Patients Receiving Androgen Deprivation Therapy for Recurrent Prostate Cancer: A Post Hoc Analysis of the PR.7 Trial, Laurence Klotz, Chantal Guillemette, Éric Lévesque, Yves Fradet, Frédéric Pouliot, Patrick Caron, Véronique Turcotte, France-Hélène Joncas, Keyue Ding, Azik Hoffman, Paul Toren, 2023, 10.1158/1078-0432.c.6529157
  • Rational cotargeting of Pim-1 and Akt in prostate cancer, Amina Zoubeidi, Paul Toren, Expert Review of Anticancer Therapy, 2013, 10.1586/14737140.2013.816461
  • Association des Urologues du Québec Congrès Annuel 2022 - Résumés., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2022, 10.5489/cuaj.8204
  • Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate Cancer in Preclinical Models., Zoubeidi A, Gleave ME, Fazli L, Davies BR, Crafter C, Cordonnier T, Kim S, Toren P, European urology, 2015, 10.1016/j.eururo.2014.08.006
  • Canadian Urological Association, 63rd Annual Meeting, Edmonton, AB, June 22-25, 2008., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2008
  • Northeastern Section of the American Urological Association 73rd Annual Meeting Abstracts., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021, 10.5489/cuaj.7599
  • Analysis of the translatome in solid tumors using polyribosome profiling/RNA-Seq, Rachid Mazroui, Paul Toren, Edouard W. Khandjian, Arnaud Droit, Valerie Grenier St-Sauveur, Pauline Adjibade, Journal of Biological Methods, 2016, 10.14440/jbm.2016.151
  • Using ex vivo culture to assess dynamic phenotype changes in human prostate macrophages following exposure to therapeutic drugs., Toren P, Bergeron A, Gris T, Pelletier JF, Berrehail Z, Park A, Joncas FH, Boibessot C, Scientific reports, 2021, 10.1038/s41598-021-98903-y
  • The effect of nerve-sparing surgery on patient-reported continence post-radical prostatectomy., Trachtenberg J, Fleshner N, Kalnin R, Nesbitt M, Matthew A, Alibhai SM, Toren P, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2009
  • 2010 CUA Abstracts., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2010
  • Interpreting Testosterone and Concomitant Prostate Specific Antigen Values during Androgen Deprivation Therapy for Recurrent Prostate Cancer, Paul Toren, Laurence Klotz, Keyue Ding, Juanita M. Crook, Frédéric Pouliot, Lily Summers-Trasiewicz, Samuel Tremblay, Journal of Urology, 2021, 10.1097/JU.0000000000001946
  • Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancer, Martin E Gleave, Paul J Toren, Asian Journal of Andrology, 2013, 10.1038/aja.2013.38
  • Sex steroid modulation of macrophages within the prostate tumor microenvironment., Toren P, Fradet Y, Lacombe L, Guillemette C, Gaignier F, Joncas FH, Gris T, Boibessot C, Berrehail Z, American journal of clinical and experimental urology, 2022
  • Patients' perceptions on active surveillance for the treatment of small renal masses., Richard PO, Tétu A, Foley V, Couture F, Couture F, Toren P, Gaboury I, Kassouf W, Lavallée LT, Hudon C, Charbonneau G, Urologic oncology, 2022, 10.1016/j.urolonc.2022.07.005
  • Is 24-hour urinary calcium a surrogate marker for dietary calcium intake?, Norman RW, Toren PJ, Urology, 2005, 10.1016/j.urology.2004.10.025
  • PEG10 is associated with treatment-induced neuroendocrine prostate cancer., Zoubeidi A, Vahid S, Colins C, Bishop JL, Toren P, Akamatsu S, Bidnur S, Thaper D, Kim S, Journal of molecular endocrinology, 2019, 10.1530/jme-18-0226
  • Small incidentally discovered testicular masses in infertile men--is active surveillance the new standard of care?, Lo KC, Jarvi K, Grober ED, Lecker I, Roberts M, Toren PJ, The Journal of urology, 2010, 10.1016/j.juro.2009.12.012
  • Switching from a GnRH agonist to a GnRH antagonist in prostate cancer patients: A systematic review and meta-analysis, Paul Toren, Neil Fleshner, Christopher J.D. Wallis, Kaleem S. Atchia, Canadian Urological Association Journal, 2019, 10.5489/cuaj.5996
  • Targeting the PI3K/Akt pathway in prostate cancer: Challenges and opportunities (Review), AMINA ZOUBEIDI, PAUL TOREN, International Journal of Oncology, 2014, 10.3892/ijo.2014.2601
  • 2012 CUA Abstracts., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2012
  • 18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) is accurate for high-grade prostate cancer bone staging when compared to bone scintigraphy., Pouliot F, Buteau FA, Beauregard JM, Fradet V, Toren P, Tiguert R, Lodde M, Lacombe L, Fradet Y, Dujardin T, Lavallée É, Dubois G, Goulet CR, Otis-Chapados S, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021, 10.5489/cuaj.7107
  • Catastrophic sepsis and hemorrhage following transrectal ultrasound guided prostate biopsies, John Trachtenberg, Roshan Razik, Paul Toren, Canadian Urological Association Journal, 2013, 10.5489/cuaj.785

Contribution à l'enseignement aux cycles supérieurs

Étudiant(e)s dirigé(e)s*

Depuis 2020/05
  • Geneviève Trépanier - Maîtrise avec mémoire - En cours
  • Kassim Kourbanhoussen - Post-doctorat - En cours
  • Typhaine Gris - Post-doctorat - En cours

Encadrement d'étudiant(e)s

Direction de recherche dans les domaines suivants :

  • Microbiologie-immunologie

En savoir plus sur les programmes

Disponibilité d'encadrement d'étudiant(e)s

Ce (cette) professeur(e) est présentement à la recherche d'étudiant(e)s.

Envoyer un courriel
*Les supervisions d’étudiant(e)s de 1er cycle en stage de recherche et de résident(e)s aux études médicales postdoctorales seront répertoriées ultérieurement.
Mettre à jour mon profil de professeur(e)